Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Click here to view

Presentation

Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency

Download PDF